Abstract
Seven of the top ten best selling drugs in the US have an orphan status. We estimate cost savings of requiring companies to return their tax credit once the orphan drug has generated at least $1 billion in annual sales revenue.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
